Abbott Reports Study Results Evaluating the i-STAT TBI Plasma Test for the Prediction of the Outcomes Due to Brain Injury
Shots:
- The study evaluated the levels of GFAP & UCH-L1 present in blood plasma within 24hrs of injury using the i-STAT TBI Plasma Test in patients (n=1696) with TBI vs GOSE analysis of biomarker levels in patients after 6mos.
- The results demonstrated that the high levels of biomarkers, GFAP & UCH-L1 correlate with death/severe injury. Additionally, the prediction rate of day-of-injury blood test on the same timepoint was found to be 86% for both GFAP & UCH-L1 vs 87% for GFAP & 89% for UCH-L1 @6mos.
- Abbott & the US DoD jointly developed the TBI blood test whereas Abbott expects to receive the FDA clearance under BTD for the TBI test on its Alinity I (CE marked) & ARCHITECT core laboratory instruments
Ref: PR Newswire | Image: Abbott
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
